- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06667908
Un estudio de JNJ-90301900 en combinación con quimiorradiación seguida de inmunoterapia de consolidación para el cáncer de pulmón de células no pequeñas (NSCLC) (CONVERGE)
Un estudio de fase 2, aleatorizado, abierto y controlado de forma activa de JNJ-90301900 en combinación con quimiorradiación seguida de Durvalumab en el NSCLC en estadio III localmente avanzado e irresecable
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Study Contact
- Número de teléfono: 844-434-4210
- Correo electrónico: Participate-In-This-Study1@its.jnj.com
Ubicaciones de estudio
-
-
-
Camperdown, Australia, 2050
- Reclutamiento
- Chris O'Brien Lifehouse
-
Herston, Australia, 4029
- Reclutamiento
- Royal Brisbane and Women's Hospital
-
Nedlands, Australia, 6009
- Reclutamiento
- Sir Charles Gairdner Hospital
-
North Ryde, Australia, 2109
- Reclutamiento
- Macquarie University
-
Parkville, Australia, 3050
- Reclutamiento
- Royal Melbourne Hospital
-
-
-
-
-
Barretos, Brasil, 14784 400
- Reclutamiento
- Fundacao Pio XII
-
São Paulo, Brasil, 05651 901
- Reclutamiento
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasil, 01308 050
- Reclutamiento
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
-
-
-
-
Madrid, España, 28041
- Reclutamiento
- Hosp. Univ. 12 de Octubre
-
Pamplona, España, 31008
- Reclutamiento
- Clinica Univ. de Navarra
-
Santiago de Compostela, España, 15706
- Reclutamiento
- Hosp. Clinico Univ. de Santiago
-
Valencia, España, 46026
- Reclutamiento
- Hosp. Univ. I Politecni La Fe
-
-
-
-
California
-
La Jolla, California, Estados Unidos, 92037
- Reclutamiento
- Moores Cancer Center at UC San Diego Health
-
-
Connecticut
-
Farmington, Connecticut, Estados Unidos, 06030
- Terminado
- University of Connecticut Health Center
-
New Haven, Connecticut, Estados Unidos, 06519
- Reclutamiento
- Yale University
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- Reclutamiento
- University of Miami
-
Orlando, Florida, Estados Unidos, 32806
- Reclutamiento
- Orlando Health Cancer Institute
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30306
- Reclutamiento
- Emory University Winship Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Beth Israel Deaconess Medical Center
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63130
- Reclutamiento
- Washington University in St Louis
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Reclutamiento
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Reclutamiento
- NYU Langone Health
-
New York, New York, Estados Unidos, 10065
- Reclutamiento
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Reclutamiento
- University of North Carolina at Chapel Hill
-
Pinehurst, North Carolina, Estados Unidos, 28374
- Reclutamiento
- FirstHealth of the Carolinas
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Reclutamiento
- University Hospitals Cleveland Medical Center
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Reclutamiento
- Oregon Health And Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- University of Pennsylvania
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- MD Anderson Cancer Center
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05401
- Reclutamiento
- University of Vermont Medical Center
-
-
-
-
-
Brest, Francia, 29200
- Reclutamiento
- Hopital De La Cavale Blanche
-
Marseille, Francia, 13015
- Reclutamiento
- Hopital Nord Marseille
-
Paris, Francia, 75248
- Reclutamiento
- Institut Curie
-
Paris, Francia, 75020
- Reclutamiento
- Hopital Tenon
-
Rouen, Francia, 76000
- Reclutamiento
- CHU Rouen Hopital Charles Nicolle
-
Villejuif, Francia, 94805
- Reclutamiento
- Gustave Roussy
-
-
-
-
-
Shatin, Hong Kong
- Reclutamiento
- Prince of Wales Hospital
-
-
-
-
-
Amsterdam, Países Bajos, 1066 CX
- Reclutamiento
- Antoni van Leeuwenhoek
-
Nijmegen, Países Bajos, 6525 GA
- Reclutamiento
- Radboud Umcn
-
-
-
-
-
Dongguan, Porcelana, 523109
- Reclutamiento
- Dongguan People s Hospital
-
Guangzhou, Porcelana, 510080
- Reclutamiento
- The First Affiliated Hospital Sun Yat sen University
-
Jinan, Porcelana, 250117
- Reclutamiento
- The Affiliated Cancer Hospital of Shandong First Medical University
-
-
-
-
-
London, Reino Unido, NW1 2BU
- Reclutamiento
- University College London Hospitals
-
-
-
-
-
Istanbul, Turquía (Türkiye), 34899
- Reclutamiento
- Marmara University Pendik Training Hospital
-
Sakarya, Turquía (Türkiye), 54100
- Reclutamiento
- Sakarya University Training and Research Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening
- Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization
- Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification
- Have at least 1 target lesion (primary lung lesion or involved lymph node[s]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
Exclusion Criteria:
- Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression
- Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV
- Another concurrent or prior primary malignancy within the last 36 months at informed consent
- Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab
- History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Part 1: Cohort A and Cohort B
Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (cohort A: 22% gross tumor volume [GTV] and cohort B: 33% GTV) along with cCRT (concurrent chemotherapy with radiation therapy) followed by consolidation immunotherapy (cIT) to evaluate feasibility of JNJ-90301900 injection procedure. |
JNJ-90301900 will be injected intratumorally and/or intranodally. Durvalumab will be administered as intravenous (IV) infusion as cIT. Radiation by intensity modulated radiation therapy (IMRT) will be administered. Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy. Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy. |
|
Experimental: Part 2: Arm A and Arm B
Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (Arm A: 22% GTV and Arm B: 33% GTV) along with cCRT followed by cIT to evaluate the efficacy and safety of JNJ-90301900. |
JNJ-90301900 will be injected intratumorally and/or intranodally. Durvalumab will be administered as intravenous (IV) infusion as cIT. Radiation by intensity modulated radiation therapy (IMRT) will be administered. Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy. Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy. |
|
Comparador activo: Part 2: Arm C: (Control treatment)
Participants will receive treatment with cCRT followed by cIT as control treatment to evaluate the efficacy and safety of JNJ-90301900. |
Durvalumab will be administered as intravenous (IV) infusion as cIT. Radiation by intensity modulated radiation therapy (IMRT) will be administered. Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy. Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Response Rate (ORR) Using Independent Central Review (ICR) Assessment
Periodo de tiempo: Up to 2 Years and 2 months
|
ORR is defined as the percentage of participants who have a best response of complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1 using ICR assessments. |
Up to 2 Years and 2 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Response Rate (ORR) Post-cCRT and Pre-cIT
Periodo de tiempo: Up to 12 Weeks
|
Objective response rate is defined as percentage of participants who achieve CR or PR, post-concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) and pre-consolidation immunotherapy (cIT) based on investigator's assessment according to RECIST v1.1. |
Up to 12 Weeks
|
|
Disease Control Rate (DCR) Post-cCRT and Pre-cIT
Periodo de tiempo: Up to 12 Weeks
|
DCR is defined as percentage of participants who achieve CR, PR and stable disease post-cCRT and pre-cIT based on investigator's assessment according to RECIST v1.1. |
Up to 12 Weeks
|
|
Objective Response Rate (ORR) as Assessed by the Investigator
Periodo de tiempo: Up to 2 Years and 2 months
|
ORR is defined as the percentage of participants who have a best response of CR or PR using RECIST v1.1 as assessed by the investigator. |
Up to 2 Years and 2 months
|
|
Progression Free Survival (PFS)
Periodo de tiempo: Up to 2 Years and 2 months
|
PFS is defined as the time from the enrollment/randomization until disease progression or death due to any cause according to RECIST v1.1. |
Up to 2 Years and 2 months
|
|
Duration of Response (DoR)
Periodo de tiempo: Up to 2 Years and 2 months
|
DoR will be calculated among responders from the date of initial documentation of a response to the date of first documented evidence of relapse according to RECIST v1.1, or death due to any cause, whichever occurs first. |
Up to 2 Years and 2 months
|
|
Time to Locoregional Failure (LRF)
Periodo de tiempo: Up to 2 Years and 2 months
|
Time to LRF is defined as the time from enrollment/randomization to the first LRF using ICR assessments. |
Up to 2 Years and 2 months
|
|
Time to Distant Failure (DF)
Periodo de tiempo: Up to 2 Years and 2 months
|
Time to DF is defined as the time from enrollment/randomization to the first DF using ICR assessments. |
Up to 2 Years and 2 months
|
|
Number of Participants with Treatment-Emergent Adverse Event (TEAE) Related to Study Treatment
Periodo de tiempo: Up to 2 Years and 2 months
|
TEAE is defined as any new or worsening adverse event (AE) occurring at or after the initial administration of study treatment through the day of last dose of study treatment received plus 30 days or prior to the start of subsequent anticancer therapy (non-durvalumab), whichever is earlier, or any follow-up AE with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent anticancer therapy, or any AE that is considered treatment-related regardless of the start date of the event. TEAEs related to JNJ-90301900 injection procedure, JNJ-90301900, RT, ChT, or cIT will be reported. |
Up to 2 Years and 2 months
|
|
Number of Participants Reporting Laboratory Parameters, Physical Examination, Vital Signs Including Eastern Cooperative Oncology Group (ECOG) Performance Status Abnormalities
Periodo de tiempo: Up to 2 Years and 2 months
|
Participants with laboratory parameters, physical examination, vital signs including ECOG performance status abnormalities will be reported. |
Up to 2 Years and 2 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Johnson & Johnson Enterprise Innovation Inc. Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 90301900NSC2001
- 90301900NSC2001 (Otro identificador: Janssen Research & Development, LLC)
- 2024-518276-32-00 (Identificador de registro: EUCT number)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .